Development of Immunological Reagents for the Identification of New World Monkey Biomarkers

项目摘要 绒猴、松鼠猴和猫头鹰猴是新世界猴（NWM），在美国被广泛研究。 广泛的研究领域，包括感染，视觉，听觉，社会行为，认知， 神经退行性疾病、生殖和基因操纵。NWM的一个关键缺点是 动物模型是目前可用的免疫学试剂的有限数量， 三千三百万年的进化分歧。研究工具的稀缺降低了 这些非人类的灵长类动物此R24应用程序的目标是通过生成 抗体和验证免疫学测定，鉴定炎症的重要NWM生物标志物， 代谢，目前缺乏试剂。炎症是衰老过程中的一个常见过程， 肥胖和病理学，如传染病、多发性硬化和年龄相关的神经退行性疾病 所有这些疾病都是在这些物种中模拟的。待产生的NWM炎症生物标志物 包括C-反应蛋白（CRP）、白细胞介素-4（IL-4）、IL-6、IL-10、干扰素γ-诱导蛋白10 （CXCL 10，IP-10）、颗粒酶B和表面糖蛋白CD 69。胃肠激素的产生， 对于代谢综合征研究的验证至关重要，包括胰岛素、脂联素和瘦素。为了 为了实现我们的目标，我们召集了一个由学术和研究机构的科学家组成的团队， 生物技术公司专业生产兽用和人用试剂。我们将 在真核细胞中产生NWM蛋白，并使用重组绒猴蛋白产生单克隆抗体， 抗体（mAb）（特异性目标1）。然后，我们将使用绒猴重组蛋白来鉴定 表位特异性，选择也识别松鼠猴和猫头鹰猴的单克隆抗体 同源物，并确定最佳抗体对的技术，如ELISA，ELISPOT，Luminex， 细胞内细胞因子染色（ICS）测定（SA 2）。最后，这些免疫学试验将通过以下方法进行验证： 从暴露于短暂代谢和炎症的NWM的血浆等分试样中获得的样品 激发，和来自离体刺激的NWM细胞（SA 3）。在这个项目的最后，研究人员在 人类疾病的不同NWM模型将获得研究工具，以改善其 临床前模型。将开发一个资源网站，以宣传试剂的供应情况，跟踪 这些试剂在生物医学研究中的影响，并分发协议和SOP。发展这些 试剂是trans-NIH感兴趣的，将增加绒猴，松鼠猴和猫头鹰的翻译价值 猴子模型，并将扩大从这些动物获得的科学数据。

PROJECT SUMMARY Marmosets, squirrel monkeys, and owl monkeys are New World Monkeys (NWM) studied extensively in a broad array of research areas, including infection, vision, audition, social behavior, cognition, neurodegenerative diseases, reproduction, and genetic manipulation. One critical shortcoming of the NWM animal models is the limited number of immunological reagents that are currently available due to more than 33 million of years of evolutionary divergence. This scarcity of research tools reduces the translational value of these nonhuman primates. The goal of this R24 application is to remedy this deficiency by generating antibodies and validating immunological assays that identify important NWM biomarkers of inflammation and metabolism, for which there is currently lack of reagents. Inflammation is a common process involved in aging, obesity, and pathologies such as infectious diseases, multiple sclerosis, and age-related neurodegenerative disorders, all of which are being modeled in these species. The NWM inflammatory biomarkers to be produced include C-reactive protein (CRP), interleukin-4 (IL-4), IL-6, IL-10, interferon gamma-inducible protein 10 (CXCL10, IP-10), granzyme B, and the surface glycoprotein CD69. Gastrointestinal hormones to be produced, critical for validation of studies of metabolic syndrome, include insulin, adiponectin, and leptin. In order to accomplish our goal, we have assembled a team of scientists from academic and research institutions and a biotechnology company specialized in the production of reagents of veterinary and human use. We will produce NWM proteins in eukaryotic cells, and use the recombinant marmoset proteins to produce monoclonal antibodies (mMabs) in mice (Specific Aim 1). We will then use the marmoset recombinant proteins to identify epitope specificity of these mAbs, select the ones that also recognize squirrel monkey and owl monkey homologues, and identify optimal antibody pairs for techniques such as ELISA, ELISPOT, Luminex, and intracellular cytokine staining (ICS) assays (SA 2). Finally, these immunological assays will be validated with samples obtained from plasma aliquots from NWM exposed to transient metabolic and inflammatory challenges, and from ex vivo stimulated NWM cells (SA 3). At the end of this project, researchers working in different NWM models of human disease will have access to research tools for improved validation of their preclinical models. A resource website will be developed to disseminate the availability of reagents, to track the impact of these reagents in biomedical studies, and to distribute protocols and SOPs. Development of these reagents is of trans-NIH interest, will increase the translational value of marmoset, squirrel monkey and owl monkey modles, and will expand the scientific data obtained from these animals.